Latest news with #CME-accredited
Mid East Info
06-08-2025
- Business
- Mid East Info
WHX Dubai and WHX Labs Dubai to combine in 2026 to form the world's largest healthcare event - Middle East Business News and Information
More than 270,000 professionals from 180 countries and over 4,800 exhibitors will come together in Dubai for one week to shape the industry The events take place from 9-13 February 2026, in two iconic locations – Dubai Exhibition Centre (DEC) and Dubai World Trade Centre (DWTC) – forming a city-wide event Together, WHX Dubai and WHX Labs Dubai will transform Dubai into a global hub for healthcare innovation and collaboration Dubai, United Arab Emirates, August 2025 : Informa has announced the launch of the world's largest healthcare event, following the decision to hold two flagship events simultaneously in 2026. From 9-13 February 2026, WHX Dubai (formerly Arab Health) and WHX Labs Dubai (previously Medlab Middle East) will bring together more than 270,000 healthcare leaders from 180 countries and over 4,800 exhibitors, transforming Dubai into a global healthcare hub and an incubator for medical advancement. For decades, these events have positioned Dubai at the centre of global healthcare discussions. Co-timed in 2026, under the patronage of the UAE Ministry of Health and Prevention, they will combine to create the world's largest healthcare event – a city-wide opportunity for dealmaking, networking and knowledge-sharing that addresses universal healthcare and laboratory challenges. WHX Dubai will be held from 9-12 February at Dubai Exhibition Centre (DEC) in Expo City Dubai, marking the first time in its 50-year history that the event will take place outside the Dubai World Trade Centre (DWTC). The show will attract an international audience and serve as a global platform for innovation, enabling exhibitors to showcase solutions across nine diverse product sectors, including medical devices, imaging and diagnostics, and healthcare infrastructure. The 50 th edition of the event, which took place earlier this year, generated a record-breaking $2.57 billion in business value, with each exhibitor experiencing an average impact of $2.14 million. WHX Dubai 2026 is set to advance global health with a forward-thinking programme that includes seven CME-accredited conferences and over 250 speakers. This edition will introduce four new certified boot camps and three dedicated stages: the Future X Stage for cutting-edge ideas; the Frontiers Stage, which will present the latest advancements in science, wellness, and life sciences; and the Visionary Stage, where global leaders will share insightful perspectives on investment, leadership, artificial intelligence, and ESG. As it celebrates its 25th anniversary in 2026, WHX Labs Dubai will be held from 10-13 February at DWTC. Under the banner of '25 Years of Laboratory Innovation: Uniting Communities for Better Health' , the event will showcase excellence in laboratories, diagnostics and precision medicine. Last year, the WHX Labs Dubai generated $621 million in business. It served as a platform connecting key buyers, government ministries, and decision-makers who are driving diagnostics-related innovation and investment in the Middle East. WHX Labs Dubai will highlight the latest advancements from across the medical lab ecosystem through eight product pillars. Additionally, the 25th Annual Laboratory Management and Medicine Congress will feature eight CME-accredited scientific conference tracks with 250 global thought leaders and laboratory specialists. Attendees can also engage in industry-defining conversations at the WHX Labs Roundtables and participate in two new clinician conferences: the Precision Health Global Forum and the Antimicrobial Resistance Leadership Global Summit. Solenne Singer, Senior Vice President at Informa Markets, said: 'WHX Dubai and WHX Labs Dubai are both well-established events with a proven track record of advancing knowledge and trade at both regional and global levels. We are delighted to host them concurrently to form the world's largest healthcare event, which will transform Dubai into a hub for the global healthcare ecosystem for five enlightening days. 'Dubai's unique position will enable bold ideas and breakthroughs to cross borders rapidly, accelerating the spread of solutions from one market to another while reinforcing the UAE's status as an international centre for healthcare transformation. By hosting the world's largest healthcare event, our attendees will make a significant contribution to future advances in medical excellence and innovation in the UAE and beyond.' About World Health Expo: World Health Expo (WHX) unifies Informa's healthcare events globally to enhance connection and collaboration under a single brand. By integrating each event within the Informa Markets Healthcare portfolio, WHX seeks to increase their influence, encouraging greater innovation, stronger connections, and transformative progress within the healthcare ecosystem. Born from the legacy of Arab Health, WHX Dubai is more than a meeting point; it's the catalyst for global investment, cross-border collaboration, and the next wave of healthcare innovation. As the world converges in Dubai, WHX becomes the stage where game-changing partnerships are forged and the future of healthcare is accelerated. This is where progress begins, and the world takes notice. WHX Labs Dubai is the region's leading platform for laboratory innovation, diagnostics, and scientific discovery. Bringing together global experts, suppliers, and healthcare professionals, it's where the future of lab technology is accelerated, and where the next breakthroughs in patient care begin. WHX Dubai will be held from 9-12 February at the Dubai Exhibition Centre (DEC) in Expo City Dubai. WHX Labs Dubai will be held from 10-13 February at DWTC.
Yahoo
10-06-2025
- Health
- Yahoo
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
Nation's first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer. In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the American Lung Association, Lung Cancer is the deadliest of all cancers, killing almost as many Americans annually as breast, prostate, and colon cancers combined. As part of this collaboration, Biodesix and APAPP will introduce new programs to educate and empower providers that practice in diverse care settings, both rural and metropolitan, managing large diverse patient populations, often with minimal resources. 'We are excited to collaborate in building awareness on how to improve patient care and outcomes for earlier detection and diagnosis of lung cancer through Biodesix blood tests,' said Scott Hutton, CEO of Biodesix. 'Sadly, the latest statistics indicate that 1 in 18 Americans will receive a lung cancer diagnosis in their lifetime. We want patients and providers to know that there are diagnostic options available to expedite earlier diagnosis and to personalize treatment decisions.' 'APPs are some of the most patient-centric and patient-driven individuals within the healthcare system,' said Corinne Young, President & Founder, Association of Pulmonary Advanced Practice Providers. 'An important part of supporting patients with lung nodules or with a lung cancer diagnosis is to be educated on the diagnostic tools that can give the patients . APAPP is happy to partner with Biodesix to further our commitment to support our professional members so that they may provide the best patient care options.' About APAPP APAPP is the first association solely focused on Advanced Practice Providers (APPs) working in the realms of pulmonary medicine. For the first time, Nurse Practitioners and Physician Assistants can join together under one membership to work towards a common goal of excellence in pulmonology medicine. About Biodesix Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit Contacts: APAPP:Corinne Young, MSN, FNP, FCCPPresident & Founder, APAPPcorinne@ (719) 425-7040 Biodesix:Natalie St. Denis, Director Corporate (720) 925-9285
Yahoo
10-06-2025
- Health
- Yahoo
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
Nation's first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer. In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the American Lung Association, Lung Cancer is the deadliest of all cancers, killing almost as many Americans annually as breast, prostate, and colon cancers combined. As part of this collaboration, Biodesix and APAPP will introduce new programs to educate and empower providers that practice in diverse care settings, both rural and metropolitan, managing large diverse patient populations, often with minimal resources. 'We are excited to collaborate in building awareness on how to improve patient care and outcomes for earlier detection and diagnosis of lung cancer through Biodesix blood tests,' said Scott Hutton, CEO of Biodesix. 'Sadly, the latest statistics indicate that 1 in 18 Americans will receive a lung cancer diagnosis in their lifetime. We want patients and providers to know that there are diagnostic options available to expedite earlier diagnosis and to personalize treatment decisions.' 'APPs are some of the most patient-centric and patient-driven individuals within the healthcare system,' said Corinne Young, President & Founder, Association of Pulmonary Advanced Practice Providers. 'An important part of supporting patients with lung nodules or with a lung cancer diagnosis is to be educated on the diagnostic tools that can give the patients . APAPP is happy to partner with Biodesix to further our commitment to support our professional members so that they may provide the best patient care options.' About APAPP APAPP is the first association solely focused on Advanced Practice Providers (APPs) working in the realms of pulmonary medicine. For the first time, Nurse Practitioners and Physician Assistants can join together under one membership to work towards a common goal of excellence in pulmonology medicine. About Biodesix Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit Contacts: APAPP:Corinne Young, MSN, FNP, FCCPPresident & Founder, APAPPcorinne@ (719) 425-7040 Biodesix:Natalie St. Denis, Director Corporate (720) 925-9285Sign in to access your portfolio
Associated Press
02-05-2025
- Business
- Associated Press
myDermRecruiter Partners with Dermwise to Enhance Dermatology Education for Healthcare Providers
myDermRecruiter and Dermwise collaborate to offer advanced dermatology education, empowering healthcare providers with essential skills and resources. 'By partnering with Dermwise, we are connecting medical professionals with a cutting-edge educational platform, simplifying the learning process and equipping them with the expertise needed to excel.'— Michelle Sullentrup, CEO WASHINGTON, MO, UNITED STATES, May 2, 2025 / / -- myDermRecruiter, the leading dermatology recruitment firm in the US, has joined forces with Dermwise, a premier provider of CME-accredited online dermatology training, to help bridge the educational gap for advanced practice providers (APPs) and other healthcare professionals seeking to specialize in dermatology. With demand for skilled dermatology APPs at an all-time high, myDermRecruiter recognizes the importance of accessible, quality education in shaping the next generation of dermatology professionals. This collaboration with Dermwise ensures that APPs, as well as other medical professionals eager to enhance their dermatological expertise have access to comprehensive, flexible learning resources. 'At myDermRecruiter, we are dedicated to fostering professional growth within the dermatology industry,' said Michelle Sullentrup, CEO of myDermRecruiter. 'By partnering with Dermwise, we are connecting driven medical professionals with a cutting-edge educational platform, simplifying the learning process and equipping them with the expertise needed to excel.' Dermwise, founded in 2015 by board-certified dermatologist Dr. Roger T. Moore, was designed to alleviate the challenges of mastering dermatology by providing an expertly curated, ready-to-use didactic curriculum. The platform's fully online, self-paced courses offer a streamlined approach to dermatology education, eliminating the traditional complexities of didactic learning. Across three Dermwise courses, learners have access to over 8,500 high-resolution clinical images, offering unmatched visual reinforcement to build diagnostic accuracy and confidence. 'We're happy to be able to refer the many NPs and PAs we work with who don't have dermatology experience to such a great tool to gain practical knowledge as they try to get into the field of dermatology,' said Michelle Sullentrup, CEO of myDermRecruiter. 'Dermwise's approach makes learning accessible and engaging, and this partnership will help these professionals feel more confident and prepared as they pursue a career in dermatology.' Through this partnership, myDermRecruiter is making it easier than ever for APPs and other professionals to access high-quality dermatology education. Upon completing all three Dermwise courses, participants receive the Dermwise Dermatology Mastery Certificate—a credential showcasing commitment to dermatological excellence. Those who register using this exclusive link will receive a $250 discount on Dermwise courses. Participants in Dermwise courses are eligible to earn AMA PRA Category 1 Credits, AAPA Category 1 CME Credits and AANP contact hours, including pharmacology hours. For more information, visit or About myDermRecruiter As the nation's top dermatology recruitment firm, myDermRecruiter specializes in connecting top-tier dermatology professionals with premier career opportunities. With an extensive network and deep industry expertise, myDermRecruiter streamlines the job search process, ensuring a seamless experience for both candidates and employers. About Dermwise Dermwise provides CME-accredited online dermatology training designed for advanced practice providers and medical professionals. Dermwise aims to transform dermatology education by simplifying the didactic teaching process, making learning more efficient and accessible for professionals. The platform includes over 8,500 high-resolution clinical images spread across its three core courses, giving learners a robust, image-rich foundation in dermatology. Michelle Sullentrup myDermRecruiter CEO [email protected] Visit us on social media: Facebook LinkedIn Instagram Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
02-05-2025
- Business
- Associated Press
Dermwise Partners with myDermRecruiter to Enhance Dermatology Education for Healthcare Providers
Dermwise and myDermRecruiter team up to provide expert dermatology education, empowering healthcare providers with essential knowledge and resources. 'At Dermwise, we understand the challenges that come with mastering dermatology, and we are dedicated to providing an innovative, structured approach to learning.'— Dr. Roger T. Moore, CEO ELKHART, IN, UNITED STATES, May 2, 2025 / / -- Dermwise, a premier provider of CME-accredited online dermatology training, is proud to announce a strategic partnership with myDermRecruiter, the nation's leading dermatology recruitment firm. This collaboration is aimed at expanding educational opportunities for advanced practice providers (APPs) and other healthcare professionals looking to specialize in dermatology. As the demand for highly skilled dermatology APPs continues to grow, Dermwise is committed to making dermatology education more accessible and effective. By partnering with myDermRecruiter, Dermwise ensures that APPs and other medical professionals have access to expert-led, self-paced online courses designed to simplify the learning process and provide comprehensive dermatology training. 'At Dermwise, we understand the challenges that come with mastering dermatology, and we are dedicated to providing an innovative, structured approach to learning,' said Dr. Roger T. Moore, CEO at Dermwise. 'This partnership with myDermRecruiter enables us to reach more professionals, empowering them with the skills and confidence they need to excel in the field.' Founded in 2015 by board-certified dermatologist Dr. Roger T. Moore, Dermwise was created to alleviate the complexities of didactic learning in dermatology. The platform's fully online, self-paced curriculum allows professionals to learn at their convenience while gaining valuable, real-world dermatology knowledge. The three Dermwise courses collectively feature over 8,500 high-resolution, clinical images, providing learners with an unparalleled visual reference to support diagnostic accuracy and clinical confidence. 'We're happy to be able to refer the many NPs and PAs we work with who don't have dermatology experience to such a great tool to gain practical knowledge as they try to get into the field of dermatology,' said Michelle Sullentrup, CEO of myDermRecruiter. 'Dermwise's approach makes learning accessible and engaging, and this partnership will help these professionals feel more confident and prepared as they pursue a career in dermatology.' Through this partnership, APPs and other medical professionals can now take advantage of an exclusive $250 discount on Dermwise courses by registering through this exclusive link. Participants in Dermwise courses are eligible to earn AMA PRA Category 1 Credits, AAPA Category 1 CME Credits and AANP contact hours, including pharmacology hours. Those who complete all three courses will also earn the Dermwise Dermatology Mastery Certificate, a credential that recognizes advanced training and dedication to dermatology excellence. For more information, visit or About Dermwise Dermwise provides CME-accredited online dermatology training designed for advanced practice providers and medical professionals. Founded in 2015 by Dr. Roger T. Moore, Dermwise offers a fully online, self-paced curriculum to simplify dermatology education and make high-quality training accessible to all. The platform features over 8,500 clinical images across its three core courses, ensuring a visually rich and comprehensive learning experience. About myDermRecruiter myDermRecruiter is the nation's top dermatology recruitment firm, specializing in connecting dermatology professionals with premier career opportunities. With an extensive network and deep industry expertise, myDermRecruiter simplifies the job search process for candidates while helping practices find top talent. Kaylee Janowski Dermwise COO [email protected] Visit us on social media: Facebook LinkedIn Instagram Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
